Epilepsy Talk
$56,000 a year for an unproven drug!
October 30, 2021
Leave a Comment
Leave a Comment
Getting the FDA to retract a decision, is like getting the toothpaste back in the tube, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Whether it’s “yes” or “no,” there is no “maybe so”.
Posted in Epilepsy, Medication Issues, News, Research
Tags: $56000 a year, aducanumab, Alzheimer’s, efficiency, FDA, not proven, patients, risk, side-effects
Tags: $56000 a year, aducanumab, Alzheimer’s, efficiency, FDA, not proven, patients, risk, side-effects
About the author
Epilepsy Talk 